Objectives. To review our experience with the diagnosis and prognosis of pulmonary embolism (PE) in gynecologic oncology patients. Methods. Spiral CT pulmonary angiography (CTPA) studies on gynecologic oncology patients were collected from our radiology database from 6/2001 to 6/2003. Patient charts were retrospectively reviewed. Data were abstracted relative to presenting symptoms, demographics and laboratory and diagnostic evaluations. Patient data were compared using chi-square contingency tables and logistic regression analysis. Survival was studied using the Kaplan-Meier method and the log rank test. The effect of PE on survival was adjusted using a proportional hazards regression model. Results. One-hundred and eleven CTPA studies were performed over 2 years and 25 patients were diagnosed with PE.Both PE (n = 25) and non-PE (n = 86) groups were similar for age, race, BMI and cancer diagnosis. Tachycardia (P = 0.02, OR = 3.03 95% CI 1.16-7.94 ) and leukocytosis (P = 0.04, OR = 2.93 95% CI 1.05-8.18 ) were more frequent among PE patients and confirmed as independently prognostic of PE.All other clinical and laboratory findings were similar between patients with and without PE. Overall survival for patients with and without PE was 63% versus 94% , respectively, at 2 years (P = 0.02). Conclusion. In a gynecologic oncology patient with high clinical suspicion for PE, our clinical pre-test probability was 23.0% . Two-year mortality rates were 6-fold higher for patients diagnosed with PE. The significant overlap in clinical presentations, multiple risk factors and higher mortality rates encourage the aggressive diagnosis and treatment of PE among this population. Further work is needed to reduce the incidence and mortality rate of PE. Objectives. To review our experience with the diagnosis and prognosis of pulmonary embolism (PE) in gynecologic oncology patients. Methods. Spiral CT pulmonary angiography (CTPA) studies on gynecologic oncology patients were collected from our radiology database from 6/2001 to 6/2003 Data were abstracted relative presenting presenting symptoms, demographics and laboratory and diagnostic evaluations. Patient data were compared using chi-square contingency tables and logistic regression analysis. Survival was studied using the Kaplan-Meier method and the log rank test. The effect of PE on survival was adjusted using a proportional hazards regression model. Results. One-hundred and eleven CTPA studies were performed over 2 years and 25 patients were diagnosed with PE.Both PE (n = 25) and non-PE Tachycardia (P = 0.02, OR = 3.03 95% CI 1.16-7.94) and leukocytosis (P = 0.04, OR = 2.9) were similar for age, race, BMI and cancer diagnosis 3 95% CI 1.05-8.18) were more among among PE patients and confirmed as independently prognostic of PE. All other clinical and laboratory findings were similar between patients with and without PE. Overall survival for patients with and without PE was 63% versus 94 %, respectively, at 2 years (P = 0.02). Conclusion. In a gynecologic oncology patient with high clinical suspicion for PE, our clinical pre-test probability was 23.0%. Two-year mortality rates were 6-fold higher for patients diagnosed with PE. The significant overlap in clinical presentations, multiple risk factors and higher mortality rates encourage the aggressive diagnosis and treatment of PE among this population. Further work is needed to reduce the incidence and mortality rate of PE.